The review covered efficacy and safety outcomes for metastatic colorectal cancer and considered evidence in the first line and in the third line or beyond. First-line evidence was limited to elderly cohorts receiving capecitabine with an EGFR-directed antibody. Among those treated with capecitabine plus cetuximab, median progression-free survival was 7.2 months and median overall survival was 17.1 months.

In the cohort receiving capecitabine plus panitumumab, the corresponding medians were 7.5 and 23.7 months. Indeed, the review’s conclusion cautioned that capecitabine should not be used together with anti-EGFR antibodies. In studies of third-line or later treatment, median progression-free survival ranged from 2.4 months for trifluridine/tipiracil plus cetuximab to 5.8 months for trifluridine/tipiracil plus panitumumab.

Median overall survival ranged from 9.8 to 14.2 months, respectively. S-1 plus cetuximab was associated with a median progression-free survival of 5.5 months and median overall survival of 13.6 months. The authors described the toxicity profile of trifluridine/tipiracil combined with an EGFR-directed antibody as manageable in the available evidence for RAS wild-type metastatic colorectal cancer, identifying this approach as feasible and promising for some frail patients.

The small number of publications, combined population of 262 participants, and limited first-line evidence mean that the reported activity requires confirmation in prospective studies.

Subject of Research: Systematic review of oral fluoropyrimidines with EGFR-directed antibodies in frail metastatic colorectal cancer

Article Title: Combination of oral fluoropyrimidines and EGFR-directed antibodies in frail patients with metastatic colorectal cancer: a systematic review

Article References: Hasenburg, A. A., Stintzing, S., & Stahler, A. (2026). Combination of oral fluoropyrimidines and EGFR-directed antibodies in frail patients with metastatic colorectal cancer: a systematic review. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06639-x

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06639-x

Keywords: metastatic colorectal cancer, frail patients, systematic review, trifluridine/tipiracil, EGFR antibodies, cetuximab, panitumumab, capecitabine, S-1, RAS wild-type, Combination, oral

The research team, led by Xinwei Wu, Danni Wang, Yangbin Shi and senior authors Baohui Han and Wei Zhang, analyzed the records of 512 patients with previously untreated stage III or IV EGFR-mutant non-small cell lung cancer who began therapy between January 2017 and December 2023. Because patients were not randomly assigned to treatment groups, the investigators used propensity-score matching, a statistical technique that pairs patients across groups according to similar baseline characteristics such as age, sex, smoking history, disease stage and mutation type. After this 1:2 matching, 364 patients formed the balanced comparison cohort, allowing the team to estimate treatment effects while minimizing the confounding that plagues observational data.

The biological logic behind the two competing strategies is worth unpacking. First-generation inhibitors such as gefitinib and erlotinib reversibly block the mutated EGFR signaling hub that drives tumor growth, while second-generation drugs like afatinib bind irreversibly and target a broader family of related receptors. Third-generation inhibitors, exemplified by osimertinib, were engineered to selectively inhibit the most common sensitizing EGFR mutations while sparing the normal receptor, and to remain active against the T790M resistance mutation that frequently emerges under pressure from earlier drugs. In clinical guidelines, third-generation monotherapy is the recommended first-line standard, but in practice — particularly in health systems where the newer drug is expensive or not reimbursed — many physicians still prescribe older inhibitors in combination regimens, for example paired with chemotherapy or with a second targeted agent, in an attempt to squeeze out additional efficacy.

The access problem is far from marginal. As the authors note, as of October 2024 first-line osimertinib was not routinely reimbursed in five Asian countries, meaning that a substantial global population of patients faces exactly the choice this study examined. Direct head-to-head real-world comparisons between the two strategies had been scarce, which is what makes the new analysis a meaningful addition to the evidence base: it reflects the messy realities of clinical practice rather than the carefully curated conditions of a randomized trial.

On the primary endpoint of progression-free survival — the time a patient lives without the cancer growing or spreading — the third-generation monotherapy group clearly came out ahead. Median progression-free survival reached 20.5 months compared with 16.0 months for the combination approach, a difference that translated into a 37 percent reduction in the risk of progression or death (hazard ratio 0.63, 95 percent confidence interval 0.50 to 0.80, P less than 0.001). Importantly, the benefit was not confined to a narrow slice of patients. It held across both sexes, among smokers and never-smokers, in stage III and stage IV disease alike, in older patients, in those with good performance status, in patients with adenocarcinoma histology, in those whose tumors carried the exon 19 deletion — the most common sensitizing EGFR alteration — and in patients without brain metastases at baseline.

Tumor shrinkage, by contrast, told a different story. The objective response rate, which measures the proportion of patients whose tumors shrink measurably, was 63.1 percent with third-generation monotherapy versus 59.6 percent with combination therapy, a difference that was not statistically significant. The disease control rate — encompassing responses plus stable disease — was essentially identical at 99.2 percent and 99.5 percent. In other words, both strategies could suppress the cancer effectively in the short term; what separated them was durability, the length of time that control lasted before resistance emerged and the disease resumed its advance.

The most provocative finding concerned overall survival. Median overall survival was 46.1 months with third-generation monotherapy and 41.6 months with the combination strategy, a gap of four and a half months that nonetheless failed to reach statistical significance (hazard ratio 0.95, 95 percent confidence interval 0.72 to 1.26, P equal to 0.721). The explanation, the authors argue, lies in the sequencing patterns captured in the data: among patients who started on the older combination, 70.5 percent went on to receive a third-generation inhibitor in a later line of treatment after progression. Those who made that switch lived significantly longer than those who did not. In effect, the newer drug delivered much of its survival benefit even when it arrived second — a phenomenon that blurs the difference between the two initial strategies when the endpoint is measured over the entire course of care.

Tolerability data added a further consideration. Adverse-event-related discontinuation and dose reduction were both more frequent in the combination therapy group, suggesting that stacking an older EGFR inhibitor with additional agents extracts a price in side effects and treatment interruptions. For a therapy intended to be taken continuously for many months, the ability of patients to stay on the drug at full intensity is not a trivial matter; it shapes both quality of life and the effective dose delivered to the tumor over time.

The authors’ conclusion is carefully calibrated. Their findings support third-generation EGFR inhibitors as the preferred first-line option where they are accessible, reinforcing existing guideline recommendations with real-world evidence. At the same time, they acknowledge that for selected patients — particularly in settings with limited reimbursement or high out-of-pocket costs — first- or second-generation combination therapy remains a reasonable alternative, especially given that later switching to a third-generation drug can still be associated with extended survival. The retrospective design and the reliance on propensity-score matching mean residual confounding cannot be excluded, and the sequencing effect on overall survival complicates any simple interpretation of the survival endpoint. Still, for clinicians and health policymakers weighing the cost of expanding access to newer targeted agents, the study offers a quantified answer: the newer drug buys more time before progression, with fewer treatment-limiting side effects, and its benefit persists even when it is deployed later in the treatment sequence.

Beyond the immediate clinical question, the study speaks to a broader tension in modern oncology: the gap between what trials demonstrate in ideal conditions and what patients actually receive across diverse health systems. As targeted therapies proliferate, sequencing has become as consequential as selection, and evidence like this — drawn from hundreds of consecutive real patients over seven years — helps illuminate how the order of the queue shapes outcomes. For the growing number of countries still negotiating reimbursement for third-generation EGFR inhibitors, the message from Shanghai is that the wait carries a measurable cost in progression-free time, even if clever sequencing can partially, but not entirely, recover the ground later.

Subject of Research: Comparative effectiveness of first-/second-generation versus third-generation EGFR-TKI therapy in untreated advanced EGFR-mutant non-small cell lung cancer

Article Title: Comparative effectiveness of first-/second-generation EGFR-TKI combination therapy versus third-generation EGFR-TKI monotherapy in untreated locally advanced or metastatic EGFR-mutant NSCLC: a real-world, retrospective study in China

Article References: Wu, X., Wang, D., Shi, Y., Liu, B., Qian, F., Zhao, T., Lu, J., Zhang, Y., Lou, Y., Han, B., & Zhang, W. (2026). Comparative effectiveness of first-/second-generation EGFR-TKI combination therapy versus third-generation EGFR-TKI monotherapy in untreated locally advanced or metastatic EGFR-mutant NSCLC: a real-world, retrospective study in China. BMC Medicine. https://doi.org/10.1186/s12916-026-05340-7

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05340-7

Keywords: EGFR-mutant NSCLC, EGFR tyrosine kinase inhibitors, osimertinib, third-generation TKI monotherapy, combination therapy, progression-free survival, overall survival, propensity-score matching, real-world evidence, targeted therapy sequencing, lung cancer, drug reimbursement

At the heart of the disease lies a genetic lesion with extraordinary penetrance. Loss or inactivation of the VHL tumour suppressor gene occurs in up to 90 percent of ccRCC cases, and this single event reshapes the entire metabolic landscape of the tumour. Under normal conditions, the VHL protein tags hypoxia-inducible factors, or HIFs, for degradation when oxygen is plentiful. When VHL function is lost, HIF-α accumulates even in well-oxygenated tissue, producing what researchers call a pseudohypoxic state. In this state, the tumour behaves as though it were starved of oxygen, activating a transcriptional programme that supports proliferation, angiogenesis, invasion and metastasis.

This pseudohypoxic switch is far more than a curiosity of gene regulation. HIF-driven transcription reprograms how ccRCC cells acquire and process nutrients, redirecting glucose into glycolysis even when mitochondria could still burn it, promoting the uptake and storage of lipids, and altering how amino acids are scavenged and recycled. The result is a cancer cell that looks and behaves metabolically unlike its healthy neighbours, a difference that decades of cancer metabolism research have suggested should be exploitable with drugs.

The review catalogues the extent of this rewiring across several interconnected pathways. Altered glucose metabolism stands out prominently: ccRCC cells increase glucose uptake through transporters such as GLUT1 and, notably, SGLT2, a transporter better known as a target of diabetes drugs. Glycolytic enzymes including HK2, PFKFB3, PKM2 and PDK1 are upregulated or differentially regulated, reinforcing the Warburg-like preference for fermenting glucose into lactate. Lactate itself, once considered a waste product, is now understood as a signalling molecule and fuel that shapes both tumour behaviour and the surrounding microenvironment, with LDHA and monocarboxylate transporters emerging as points of control.

Lipid metabolism tells an equally striking story. Clear cell tumours are named for their characteristic cytoplasmic droplets of fat and glycogen, and the review describes how extensive lipid accumulation is not merely a by-product but an active adaptation. Enzymes and transporters governing lipid synthesis, uptake and oxidation, including ACLY, ACC, FASN, SCD1, CD36 and CPT1A, are reconfigured to supply membranes, signalling molecules and energy stores. Abnormal amino acid metabolism, particularly involving glutamine, tryptophan and arginine, adds a further layer, supplying nitrogen and carbon for biosynthesis while depleting nutrients that immune cells need to function.

That last point connects metabolism directly to one of the central clinical challenges in kidney cancer. The metabolic activities of tumour cells help construct an immunosuppressive tumour microenvironment. Lactate-rich, nutrient-depleted surroundings can blunt the activity of cytotoxic T cells and favour regulatory immune populations, and altered tryptophan and arginine catabolism is a well-established mechanism of immune suppression. This may help explain why immune checkpoint inhibitors, which have transformed treatment for many cancers, produce durable responses in only a subset of ccRCC patients, and why metabolic interventions could potentially restore sensitivity to immunotherapy.

The therapeutic implications form the core of the review’s argument. Each metabolic node identified as dysregulated represents a potential drug target, and the authors enumerate them systematically: glucose transporters GLUT1 and SGLT2, the glycolytic enzymes HK2, PFKFB3, PKM2 and PDK1, lactate regulators LDHA and the MCT family, lipid pathway proteins ACLY, ACC, FASN, SCD1, CD36 and CPT1A, and enzymes of glutamine, tryptophan and arginine metabolism. Several agents directed at these targets have already entered clinical evaluation, although the review is careful to note that progress varies considerably between targets, and that clinical translation remains uneven across the metabolic landscape.

The complexity of tumour metabolism, however, imposes real constraints on single-target strategies. Cancer cells display remarkable metabolic plasticity: when one pathway is blocked, they can compensate by routing flux through parallel routes, drawing on alternative fuels, or reprogramming upstream regulators. This buffering capacity means that inhibiting a single enzyme, however central it appears in preclinical models, may produce modest or transient clinical effects. The review acknowledges this limitation candidly, positioning metabolism-targeting not as a standalone solution but as one component of a broader therapeutic architecture.

The path forward, the authors argue, will likely depend on combination therapies and multi-target inhibitors designed to close the escape routes that tumours use to bypass metabolic blockade. Improved biomarkers are equally important, since patients/ tumours differ in their metabolic dependencies, and approaches capable of accounting for metabolic heterogeneity within individual tumours will be needed to match the right drug to the right biology. Integrating metabolic interventions with immune checkpoint inhibitors and other established treatments, including the VEGF-targeted therapies already standard in ccRCC, could offer a route toward overcoming resistance and building genuinely personalised treatment strategies.

What makes this synthesis compelling is the convergence of genetics and metabolism in a single disease. Because VHL loss is nearly universal in ccRCC, the pseudohypoxic, lipid-laden, glycolysis-dependent phenotype it produces is a shared vulnerability rather than a rare subtype feature, giving the field an unusually consistent target landscape. If combination regimens can be designed to exploit that consistency while accommodating tumour-to-tumour variability, the metabolic rewiring that has long made clear cell renal cell carcinoma distinctive may finally become the very thing that makes it treatable.

Subject of Research: Metabolic reprogramming and therapeutic targets in clear cell renal cell carcinoma

Article Title: Metabolic vulnerabilities open new therapeutic possibilities in clear cell renal cell carcinoma

Article References: Metabolic vulnerabilities open new therapeutic possibilities in clear cell renal cell carcinoma. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: clear cell renal cell carcinoma, kidney cancer, metabolism, VHL, HIF, glycolysis, lipid metabolism, immunotherapy, drug targets, tumour microenvironment, pseudohypoxia, combination therapy

What makes this perspective particularly valuable is the way it organizes a sprawling pipeline into four mechanism-based therapeutic domains: molecular-targeted therapies, immunotherapies and vaccines, oncolytic viruses and gene therapies, and agents directed at tumor metabolism and the microenvironment. This taxonomy is more than a convenient filing system. It reflects a deliberate shift away from the historical practice of treating glioblastoma as a single, uniform disease, and toward an approach in which treatments are matched to the molecular fingerprints of individual tumors. Across all four domains, the authors emphasize that patient selection is increasingly guided by biomarkers such as MGMT promoter methylation, IDH mutation status, EGFR amplification and BRAF V600E alterations. These molecular characteristics define biologically distinct patient groups and can determine who is enrolled in trials testing particular therapeutic strategies, a movement that mirrors the biomarker-driven revolution already realized in lung cancer, breast cancer and melanoma.

The biological obstacles that have frustrated glioblastoma treatment for decades remain formidable, and the review does not shy away from them. Glioblastoma tumors harbor genetically and functionally diverse populations of cancer cells, meaning that a drug that eradicates one clone may leave others to repopulate the tumor. The tumor microenvironment is profoundly immunosuppressive, populated by suppressive macrophages, myeloid-derived suppressor cells and regulatory T cells that blunt antitumor immunity. The blood-brain barrier, the brain’s highly selective vascular gatekeeper, restricts the ability of many systemically administered drugs to reach therapeutic concentrations within the tumor. Hypoxia and other features of the tumor environment further promote treatment resistance, allowing glioblastoma cells to adapt their metabolism in response to therapeutic pressure. Any honest account of the emerging pipeline must weigh each new agent against these barriers, and the Oncoscience perspective does exactly that.

Within the molecular-targeted domain, several programs stand out for their biological rationale. The review discusses approaches targeting B7-H3, CDK4/6, the RAS/MAPK signaling pathway and BRAF alterations, among other vulnerabilities. One noteworthy example is abemaciclib, a CDK4/6 inhibitor with relatively favorable brain penetration, which is being investigated in combination with the ERK inhibitor LY3214996. The logic of such a combination is elegant: blocking CDK4/6 restrains cell-cycle progression, while inhibiting ERK disrupts downstream signaling from the RAS pathway, making it harder for tumor cells to compensate through parallel routes. Regorafenib, a multi-kinase inhibitor that suppresses both angiogenic and proliferative signaling, offers a cautionary but instructive case. In the Phase 2 REGOMA trial for recurrent glioblastoma, regorafenib improved median overall survival compared with lomustine, yet it was also associated with more severe adverse events, a reminder that in a disease where the therapeutic window is narrow, efficacy and tolerability must be evaluated together.

Immunotherapy represents perhaps the most rapidly evolving arm of the pipeline. Dendritic cell vaccines, designed to expose the immune system to tumor-associated antigens and generate cytotoxic T-cell responses, continue to be refined, with DCVax-L among the most prominent examples. The review also highlights plasmid DNA vaccines INO-5401 and INO-9012 in combination with the PD-1 inhibitor cemiplimab, a strategy intended to prime immune responses against multiple tumor antigens while simultaneously releasing the brakes that glioblastoma places on T-cell activity. The overarching goal is to convert what is often called a cold tumor, immunologically silent and heavily suppressed, into one that can be recognized and destroyed by the patient’s own immune system. That conversion remains difficult, but the diversity of vaccine platforms now in testing signals a maturing understanding of how to combine antigen delivery with immune checkpoint release.

Chimeric antigen receptor T-cell therapy, which has produced dramatic results in hematologic malignancies, is being adapted to confront the molecular heterogeneity that makes solid brain tumors so elusive. Because glioblastoma cells can simply stop expressing any single target antigen, investigators are developing bivalent and multivalent CAR constructs capable of recognizing more than one tumor-associated antigen at once. The perspective describes a bivalent CAR T-cell strategy targeting both EGFR and IL-13Rα2 in recurrent glioblastoma, as well as engineered tumor-infiltrating lymphocytes designed to secrete anti-PD-1 antibodies directly within tumors, effectively building the checkpoint inhibitor into the cellular therapy itself. The challenges, however, are sobering: antigen loss, T-cell exhaustion, neurotoxicity, questions about the optimal delivery route, and the hostile immunosuppressive microenvironment all remain obstacles between laboratory promise and durable clinical benefit.

Oncolytic and gene-therapy platforms are pushing the field toward treatments that exploit the very biology of tumor cells. Retroviral replicating vectors such as DB107-RRV and DB107-FC are engineered to spread selectively through dividing tumor cells and convert an otherwise innocuous prodrug into a cytotoxic compound precisely where it is needed, within the tumor itself. Other experimental gene-therapy approaches aim to couple this tumor-selective activity with immune stimulation, pairing direct cell killing with the activation of antitumor immunity. These strategies remain strictly investigational, and the review is candid about their challenges, which include achieving adequate delivery across the blood-brain barrier, evading antiviral immune responses, and assembling the specialized infrastructure required to manufacture and administer such sophisticated treatments.

A fourth and increasingly active frontier targets the altered metabolism of glioblastoma cells. The review describes BPM31510, an agent that targets mitochondrial bioenergetics and redox homeostasis, and ASC40, an inhibitor of fatty acid synthase, both of which are being evaluated in clinical trials. The rationale is compelling: glioblastoma cells display remarkable metabolic flexibility, rewiring their energy production and lipid synthesis to survive under the hypoxic and nutrient-limited conditions that characterize the tumor core. By disrupting these metabolic adaptations, investigators hope to starve tumor cells of the biochemical options they use to endure treatment pressure. Because metabolic vulnerabilities can differ between tumors and even between regions of the same tumor, this domain may ultimately depend heavily on the same biomarker-guided selection strategies that are reshaping targeted therapy.

Despite the expanding arsenal, the authors are unambiguous that none of these emerging approaches has yet displaced the temozolomide-based standard of care. The evolving strategy is instead centered on biomarker-directed combinations, in which targeted, immune-based or metabolic treatments are layered onto existing therapy for molecularly defined groups of patients. As the authors put it, the combination of precision molecular targeting with new immune activation methods, CNS-based drug delivery and metabolic interference establishes a foundation for developing combination therapies that should use proven predictive biomarkers for maximum effectiveness. Major barriers persist, from intratumoral heterogeneity that allows resistant clones to escape single-target treatments, to the practical problem that differences among clinical trials in eligibility criteria, endpoints, imaging assessments and corticosteroid use make it difficult to compare results across studies. The authors argue that future progress may hinge on adaptive clinical trial platforms capable of evaluating multiple therapies and molecular subgroups simultaneously, rational combinations that attack several facets of glioblastoma biology at once, personalized neoantigen vaccines, improved methods for delivering drugs across the blood-brain barrier, and emerging liquid-biopsy and imaging biomarkers that could allow treatment response to be monitored in real time.

The broader message of the Oncoscience perspective is one of cautious, methodical optimism. The glioblastoma treatment landscape is unmistakably moving away from broadly applied cytotoxic approaches and toward mechanism-based, biomarker-guided and combination strategies, with molecular targeting, immune activation, gene and oncolytic therapies, metabolic intervention and improved CNS drug delivery all being pursued in parallel. The results of ongoing Phase II and Phase III studies will be decisive in determining which of these approaches ultimately advances toward regulatory consideration and clinical adoption. For a disease that has seen repeated waves of promising science fail at the bedside, the current pipeline’s emphasis on biological sophistication, rigorous patient selection and combination logic may prove to be exactly the kind of strategic reset that glioblastoma research has been waiting for, provided the field can translate mechanistic breadth into measurable survival gains for patients.

Subject of Research: Emerging pharmacological agents and biomarker-guided combination strategies in glioblastoma clinical trials

Article Title: Emerging glioblastoma therapies move toward biomarker-guided and combination strategies

Article References: Emerging glioblastoma therapies move toward biomarker-guided and combination strategies. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: glioblastoma, clinical trials, molecular targeted therapy, immunotherapy, CAR T-cell therapy, dendritic cell vaccines, oncolytic virus, gene therapy, tumor metabolism, blood-brain barrier, biomarkers, combination therapy

The biological basis of BCG immunotherapy is complex. When the bacterium is introduced into the bladder, it attaches to fibronectin and other extracellular matrix proteins on the surface of urothelial cells, where it is internalized by both tumor cells and antigen-presenting cells. This internalization sets off a cascade of innate immune signaling, including the activation of toll-like receptors and the release of pro-inflammatory cytokines such as interleukin-1, interleukin-6, interleukin-8, and tumor necrosis factor alpha. Over the following weeks, this acute inflammatory response evolves into an adaptive immune reaction characterized by the infiltration of CD4 and CD8 T lymphocytes, natural killer cells, and granulocytes, which together work to eliminate residual tumor cells and prevent recurrence.

However, bladder tumors are not passive targets. Over time, many lesions develop sophisticated mechanisms of immune evasion that allow them to survive despite an active local immune attack. One of the most important of these mechanisms involves the upregulation of immune checkpoint molecules, particularly programmed death-ligand 1, or PD-L1, on the surface of tumor cells. When PD-L1 engages its receptor, PD-1, on infiltrating T cells, it delivers an inhibitory signal that effectively disarms the cytotoxic response. Research has shown that PD-L1 expression in bladder tumors can increase after BCG treatment, suggesting that the very inflammation triggered by the therapy may inadvertently select for tumor clones that exploit checkpoint pathways to escape destruction.

Beyond checkpoint upregulation, tumors employ a range of additional strategies to resist immune attack. Some bladder cancers secrete immunosuppressive cytokines such as interleukin-10 and transforming growth factor beta, which dampen T cell activation and promote the recruitment of regulatory T cells. Others remodel their tumor microenvironment by increasing the density of myeloid-derived suppressor cells and tumor-associated macrophages that skew the local immune landscape away from an antitumor phenotype. Genetic alterations in tumor suppressor pathways and antigen presentation machinery can further impair the ability of the immune system to recognize malignant cells, creating a multidimensional wall of resistance that single-agent therapies struggle to penetrate.

This growing appreciation of tumor immune evasion has reshaped the therapeutic landscape. Rather than relying on BCG alone, investigators are now exploring rational combination strategies that pair BCG with agents designed to block specific escape pathways. Immune checkpoint inhibitors, particularly antibodies targeting PD-1 and PD-L1, have emerged as leading candidates for such combinations. By releasing the brakes on T cells that BCG has already activated, checkpoint blockade may restore the cytotoxic function that tumors have suppressed, creating a synergistic effect in which one agent primes the immune system and the other unleashes it.

Clinical trials are actively testing this hypothesis. Studies combining BCG with pembrolizumab, an anti-PD-1 antibody, have shown encouraging response rates in patients whose tumors did not respond to BCG alone. Other trials are evaluating combinations of BCG with interleukin-15 superagonists, which stimulate the proliferation and activation of natural killer cells and memory-like CD8 T cells, adding another layer of antitumor immunity. Gene therapy approaches, including adenoviral vectors engineered to deliver interferon alpha directly to bladder tumor cells, are also being investigated in combination with BCG and checkpoint inhibitors, aiming to enhance antigen presentation and further sensitize tumors to immune attack.

Not all combination strategies involve immunotherapy. Intravesical chemotherapy agents such as gemcitabine and docetaxel, delivered directly into the bladder to minimize systemic toxicity, are being paired with BCG and with checkpoint inhibitors in sequential and concurrent regimens. These chemotherapy agents do more than kill tumor cells directly; emerging evidence suggests they can induce immunogenic cell death, a form of tumor cell demise that releases tumor antigens and danger signals, thereby enhancing the ability of antigen-presenting cells to stimulate an antitumor T cell response. In this way, chemotherapy may act as a catalyst that amplifies the effects of immunotherapy rather than simply an additive cytotoxic agent.

The challenges ahead are considerable. Combination therapies inevitably raise questions about toxicity, as activating multiple arms of the immune system simultaneously can increase the risk of adverse effects ranging from local bladder irritation to systemic autoimmune reactions. Patient selection is another critical variable, since not all tumors respond equally to immune-based strategies, and biomarkers capable of predicting which patients will benefit from specific combinations remain an area of intense investigation. Cost and accessibility also factor into the equation, as novel immunotherapeutic agents and gene therapies can be expensive to produce and administer.

Despite these obstacles, the momentum behind combination therapy for BCG-unresponsive bladder cancer is undeniable. The convergence of deeper mechanistic insight into tumor immune evasion, the availability of agents capable of targeting specific resistance pathways, and a robust pipeline of clinical trials testing rational combinations has created a genuine inflection point in the field. For patients whose tumors once faced limited options after BCG failure, the emerging arsenal of combination strategies offers renewed hope for durable disease control and, ultimately, improved survival without the need for radical surgery.

Subject of Research: Cancer immunology and immunotherapy resistance in bladder cancer

Article Title: Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies

Article References: Daneshmand, S., Boorjian, S. A., Meeks, J. J., Lotan, Y., Kassouf, W., Kulkarni, G. S., Gontero, P., Albers, P., Jakobsen, J. S., & Juul, K. (2026). Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies. Nature Reviews Urology. https://doi.org/10.1038/s41585-026-01193-0

Image Credits: AI Generated

DOI: 10.1038/s41585-026-01193-0

Keywords: bladder cancer, BCG immunotherapy, immune evasion, immunotherapy resistance, cancer immunology, combination therapy, tumor microenvironment, immune checkpoint inhibitors, oncology, clinical research, Combination, therapy

The biological case is compelling. In the early disease course, endogenous remyelination by oligodendrocyte precursor cells, and to a lesser extent by surviving oligodendrocytes, often restores the myelin sheath to near-complete integrity. But with ageing, this repair mechanism deteriorates. Microglia that accumulate in demyelinated lesions of aged animals adopt a senescence-associated secretory phenotype, chronically upregulating pro-inflammatory mediators while losing phagocytic efficiency. Myelin debris, which contains potent inhibitors of oligodendrocyte differentiation such as myelin-associated glycoprotein and Nogo-A, therefore lingers in the lesion. Simultaneously, pro-inflammatory cytokines including IL-1β and TNF-α, along with reactive oxygen species, create a hostile milieu for oligodendrocyte development. Astrocytes undergo a parallel decline: the transition from reactive to pro-regenerative phenotypes becomes impaired with age, growth factor production falls, and reactive astrocytes secrete extracellular matrix proteins that form glial scars and release neurotoxins.

Ageing of the axon-myelin unit itself compounds the problem. Myelin progressively degenerates in the ageing brain, and the resulting debris accumulates in microglial lysosomes, increasing the clearance burden on microglia that are already less efficient. Myelinated axons depend on oligodendrocytes for metabolic support, receiving glycolytic products such as glucose and lactate to maintain axonal integrity. This support is reduced in demyelinated or thinly remyelinated axons while the energy cost of conduction rises. Furthermore, ageing white matter is more vulnerable to metabolic and ischemic stress, as demonstrated by studies showing that optic nerves from older mice suffer more severe injury during oxygen-glucose deprivation than those of young mice, a finding particularly relevant to older people with MS in whom vascular comorbidities accumulate.

Against this backdrop, the clinical track record of pro-remyelinating pharmacotherapy is sobering. Clemastine, an antihistaminic drug with antimuscarinic properties, met its primary electrophysiological endpoint in the ReBUILD trial, shortening visual evoked potential P100 latency by 1.7 milliseconds per eye, and subsequent myelin water imaging provided convergent evidence of increased myelin content in the corpus callosum. Nevertheless, the magnitude and clinical relevance of that latency change remain uncertain, and a clemastine study in progressive MS was halted after an unexpected acceleration of disability. PIPE-307, a more selective M1 receptor antagonist designed to address the unfavourable side-effect profile, was well tolerated in the phase 2 VISTA trial but failed to meet its primary endpoint of improvement in low-contrast letter acuity. Opicinumab, an anti-LINGO-1 antibody, did not delay disease progression in people with MS despite being tested as add-on therapy to anti-inflammatory disease-modifying treatments. Bexarotene produced a negative primary MRI endpoint with poor tolerability in CCMR One.

The authors contend that these translational failures stem partly from a mechanistic blind spot: most investigated remyelinating pharmaceuticals act intrinsically on oligodendrocyte precursor cells, promoting lineage progression, while insufficiently addressing the non-permissive inflammatory, senescent and extracellular-matrix-rich microenvironment of MS lesions. Preclinical evidence supports this interpretation. Combining an anti-CD20 compound with clemastine fumarate significantly enhanced remyelination, reduced inflammatory activity and improved functional recovery compared to either treatment alone in an experimental autoimmune encephalomyelitis model. Similarly, tuftsin, an immunomodulatory tetrapeptide that induces an anti-inflammatory shift in microglia and macrophages, combined with benztropine, an anticholinergic drug with remyelinating capacity, produced comparable benefits. Molecules targeting glial inflammatory signalling, such as PPARγ agonists and IL-4, enhanced oligodendrocyte development and remyelination, while the Toll-like receptor 3 agonist Poly-IC increased interleukin-33 production in oligodendrocyte precursor cells, stimulating myelin gene transcription and cell maturation. Remodelling the extracellular matrix with inhibitors of chondroitin sulfate proteoglycan synthesis led to enhanced recruitment and differentiation of oligodendrocyte precursor cells, followed by remyelination.

Into this framework, the authors introduce non-invasive brain stimulation as a mechanistically distinct therapeutic strategy. Techniques such as repetitive transcranial magnetic stimulation, transcranial direct current stimulation and transcranial alternating current stimulation modulate neural network activity without surgery, and mounting evidence from healthy and demyelinating animal models suggests that modulating neuronal activity can positively affect oligodendrocyte proliferation, differentiation and maturation, as well as subsequent remyelination. Optogenetic stimulation of a subset of neurons demonstrates the neuronal activity-dependent maturation of oligodendrocytes, while blocking synaptic release impairs central nervous system myelination. In an ethidium bromide myelin lesion model, tetrodotoxin, an action potential-inhibiting toxin, impaired oligodendrocyte development and axon remyelination, revealing the importance of axonal signalling in repair. Oligodendrocyte precursor cells express various neurotransmitter receptors, and in vitro experiments have found that silencing those receptors disrupts cell development, whereas stimulating them can effectively boost oligodendrogenesis. Interestingly, the pattern of neuronal activity seems to influence precursor cell behaviour, with high-frequency stimulation boosting proliferation while low-frequency electrical activity promotes differentiation.

Crucially, activity-dependent effects on remyelination are unlikely to be mediated exclusively through direct neuron-oligodendrocyte precursor cell communication. Astrocytes and microglia also express receptors for neurotransmitters and neuromodulators, allowing them to respond directly to extracellular signalling changes induced by neuronal activity or stimulation. Neuronal depolarization triggers potassium release at nodes of Ranvier, which is sensed by microglia via the potassium channel THIK-1, inducing a shift towards pro-regenerative microglial transcriptional states necessary for myelin debris clearance. In astrocytes, neurotransmitter and neuromodulator signalling can induce intracellular calcium responses that influence astrocytic phenotype and function; transcranial direct current stimulation-induced astrocytic calcium signalling has been linked to noradrenergic alpha-1 receptor mechanisms in the healthy mouse cortex. Preclinical studies in demyelinating models strengthen the rationale: low-intensity repetitive transcranial magnetic stimulation delivered as intermittent theta burst stimulation enhanced remyelination by increasing the number of myelin internodes elaborated by new oligodendrocytes and by supporting the myelinating capacity of surviving oligodendrocytes, while 10 Hz transcranial alternating current stimulation enhanced oligodendrogenesis and myelin repair following cuprizone-induced demyelination.

Evidence for stimulation-induced glial modulation, in contrast, comes largely from models other than demyelination. Repetitive transcranial magnetic stimulation at 10 Hz shows a remarkable capacity to inhibit astrocyte polarization towards a pro-inflammatory phenotype while promoting a shift towards pro-regenerative states in an ischemic rat model. High-frequency stimulation can shift the microglial phenotype towards regeneration via the JAK2/STAT3 pathway, attenuating white matter lesions in a post-stroke rat model. A systematic review confirms that, across multiple disease models, high-frequency stimulation consistently decreases markers of astrocyte reactivity and attenuates microglial pro-inflammatory activation. Importantly, these glial modulatory effects appear to be context-dependent and more pronounced in injured than in healthy brain tissue, suggesting that the therapeutic window may be particularly relevant in the pathological context of MS. However, the authors caution that the injury in these models is ischemic rather than immune-mediated, and whether the glial mechanisms described in ischemic and post-stroke models also apply to MS lesions remains to be demonstrated.

The authors argue that pharmacological agents and stimulation may influence different processes of the remyelination cascade, making them genuinely complementary rather than redundant. Clemastine and PIPE-307 target the muscarinic M1 receptor-mediated inhibition of oligodendrocyte precursor cell differentiation, whereas thyromimetics and bexarotene activate myelin gene expression. Metformin, on the other hand, seems to restore the responsiveness of aged precursor cells to differentiation cues. Stimulation, by contrast, mainly influences the environment in which precursor cells must differentiate as well as the axonal signals that guide myelination. First, stimulation may shift the intrinsic states of microglia and astrocytes towards regeneration and support myelin debris clearance. Second, neuronal activity influences which axons get myelinated and how many internodes are formed by new oligodendrocytes, so a drug that increases differentiation may benefit from a supplementary activity-dependent signal that directs these cells towards myelin sheath generation. Third, metformin may intrinsically act on the metabolism of aged precursor cells, whereas stimulation could improve the toxic extrinsic glial microenvironment.

Yet the authors also warn that some mechanisms of both approaches may counteract each other. Clemastine is thought to promote precursor cell differentiation mainly by antagonising muscarinic M1 receptors. If stimulation increases cholinergic signalling onto precursor cells, activation of these same receptors might act as a brake on differentiation and partly offset the effect of clemastine. This interaction has not been investigated to date, and it is unlikely to be the only antagonistic interaction between the two approaches, so possible interactions should be tested before these strategies are combined in people with MS. The effects of a combined approach may also depend on lesion stage. In active inflammatory lesions, the priority is to limit ongoing injury, and the early pro-inflammatory glial response is essential to clear myelin debris, so a stimulation-induced shift of glial cells towards pro-regenerative states may need to be delayed. In actively remyelinating lesions, the therapeutic window appears largest, as oligodendrocyte precursor cells and newly formed oligodendrocytes are present. In chronic active and inactive lesions with persistent glial activation or senescence, pro-differentiation drugs alone are unlikely to be effective, as both precursor cells are depleted and the microenvironment is hostile. Whether stimulation can reverse persistent glial activation or senescence is unknown, but adding a drug such as metformin that may rejuvenate precursor cells could offer an elegant solution.

Non-invasive brain stimulation has already been tested extensively in people with MS in clinical trials. A meta-analysis of 25 randomized controlled trials found that transcranial direct current stimulation significantly reduces fatigue with a large effect size and improves cognitive function, while repetitive transcranial magnetic stimulation reduces spasticity. A broader systematic review and network meta-analysis of 49 trials confirmed that stimulation is safe and well tolerated in people with MS, with no reports of serious adverse effects or pharmacological interactions. These trials establish a safety and feasibility foundation, but none was designed to assess remyelination as a primary endpoint, representing a critical research gap. Future trials should incorporate advanced MRI markers of myelin content, such as myelin water imaging and magnetization transfer ratio, and electrophysiological measures of conduction velocity as endpoints. Visual evoked potential latency is an attractive translational endpoint because it is inexpensive, reproducible and sensitive to conduction along a clinically relevant pathway, but it is also influenced by inflammation, temperature, axonal loss, retinal dysfunction and synaptic transmission, so a small improvement in latency should not be equated with clinically meaningful repair. Concordance across several modalities, including optical coherence tomography, low-contrast visual acuity and functional outcomes, is more informative than any single surrogate.

No single animal model reproduces the spatial heterogeneity, chronic compartmentalized inflammation, ageing and neuroaxonal loss that characterize human MS. Cuprizone and focal toxin models offer controlled demyelination and temporally predictable repair but lack a substantial adaptive immune component, while experimental autoimmune encephalomyelitis provides an inflammatory context and can reproduce chronic visual-pathway demyelination and partial remyelination. Aged and chronic cuprizone paradigms, chronic autoimmune encephalomyelitis and sequential or hybrid models should therefore be regarded as complementary platforms, each capturing a different aspect of the disease. Aged animals in particular will be needed to test whether stimulation remains effective in senescent white matter, since all preclinical stimulation studies on remyelination discussed were performed in young adult animals. For stimulation-drug combinations specifically, factorial designs that include each monotherapy, the combination and sham controls will be needed, with the interaction between modalities tested in advance to distinguish additive, synergistic and antagonistic effects. Collectively, the evidence suggests that remyelination failure in MS cannot be explained solely by impaired oligodendrocyte differentiation but also reflects a non-permissive inflammatory and age-related lesion microenvironment, and that stimulation may be a useful component of combinatorial strategies rather than a replacement for remyelinating drugs.

Subject of Research: Neuroscience

Article Title: Combining pharmacological and non-invasive brain stimulation strategies to promote remyelination in multiple sclerosis

Article References: Scheinok, T. J., De Bundel, D., Vanmierlo, T., & Van Schependom, J. (2026). Combining pharmacological and non-invasive brain stimulation strategies to promote remyelination in multiple sclerosis. Frontiers in Molecular Neuroscience, 19, Article 1980126. https://doi.org/10.3389/fnmol.2026.1980126

Image Credits: AI Generated

DOI: 10.3389/fnmol.2026.1980126

Keywords: multiple sclerosis, remyelination, non-invasive brain stimulation, oligodendrocyte precursor cells, microglia, neuroinflammation, combination therapy, Combining, pharmacological, non-invasive, brain, stimulation

The core concept behind an ADC is deceptively simple, and reviewers often describe it as a guided missile. The drug consists of three covalently joined components: a monoclonal antibody that recognizes a tumor-associated antigen, a chemical linker that holds the assembly together in the bloodstream, and a cytotoxic payload far too potent to be given as a conventional chemotherapy. The antibody does the navigation; it binds cells displaying the right surface marker and, through antigen-mediated internalization, delivers the poison selectively to the interior of the cancer cell. The theoretical payoff is a dramatic widening of the therapeutic window, since maximal damage is concentrated on tumor tissue while healthy cells are largely spared. In practice, as the review makes clear, that selectivity is never perfect, and the gap between concept and clinic has shaped the entire development history of the field.

That history spans three generations of chemistry. Early ADCs, built on murine antibodies and labile linkers, produced such heavy off-target toxicity that several were abandoned. The current era belongs to agents such as trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan (SG), which pair humanized antibodies with cleavable or stable linkers and payloads including auristatin derivatives such as monomethyl auristatin E (MMAE) and topoisomerase I inhibitors. Payload choice matters enormously: topoisomerase I inhibitors exhibit what researchers call bystander killing, in which membrane-permeable drug released from a dying tumor cell diffuses into neighboring malignant cells that express little or none of the target antigen. This property helps explain why T-DXd and SG have produced striking responses in tumors with heterogeneous antigen expression, including triple-negative breast cancer, non-small cell lung cancer, metastatic urothelial carcinoma, and HER2-low breast cancers that were previously ineligible for HER2-directed therapy.

Beyond simple payload delivery, a modern ADC is expected to do several jobs at once. The antibody component retains its natural immune functions, recruiting effector cells through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Linker stability determines how much free drug leaks into circulation, which in turn drives systemic side effects such as neutropenia and interstitial lung disease. The review emphasizes that optimizing all three modules simultaneously, antigen selection, linker chemistry, and payload, is a multi-variable engineering problem rather than a linear design task, and that this complexity explains why clinically successful ADCs remain outnumbered by the many candidates that have failed in trials.

Clinically, ADCs have become an established option for patients who have exhausted traditional treatments or developed resistance to earlier lines of therapy. The review systematically walks through the FDA-approved agents in solid tumors, highlighting overall response rates (ORR) and the therapeutic niches each drug has carved out, from HER2-positive and HER2-low breast cancer to urothelial carcinoma and lung cancer, alongside applications in hematological malignancies. The picture that emerges is one of genuine clinical transformation: diseases once treated only with blunt cytotoxic chemotherapy now have therapies that combine molecular precision with lethal payload delivery. Yet the review is equally candid that efficacy is frequently incomplete, with many patients deriving only transient benefit before disease progression.

That incomplete benefit points to the review’s central concern: acquired drug resistance. Tumors are Evolving systems, and the review organizes the escape routes cancer cells take into several mechanistic categories. Changes in the target antigen itself, through downregulation, mutation, or loss of surface expression, can starve the ADC of its docking site. Alterations in the internalization and trafficking machinery prevent the conjugate from reaching the lysosomal compartments where the linker is meant to be cleaved. Upregulation of drug efflux pumps can expel released payloads before they act, a mechanism long familiar from conventional chemotherapy. And changes in the payload’s downstream vulnerabilities, such as modifications in the DNA damage response (DDR) pathways targeted by topoisomerase I inhibitors or alterations in glutathione peroxidase 4 (GPX4) linked to ferroptosis sensitivity, can blunt the lethal effect even after successful delivery.

Just as consequential, the review argues, is the tumor microenvironment (TME), the crowded ecosystem of stromal and immune cells that surrounds a malignancy. Cancer-associated fibroblasts (CAFs), including the adipose-derived subtype (adCAFs), can form physical and biochemical barriers that shield tumor cells from circulating antibody. Myeloid-derived suppressor cells (MDSCs) dampen the immune effector functions that the antibody arm of an ADC is meant to recruit. Poorly vascularized and hypoxic regions limit drug penetration deep into tumor masses, meaning that even a perfectly designed conjugate may only reach the outer shell of a lesion. The review frames these microenvironmental factors not as secondary details but as first-order determinants of whether an ADC works, and as targets for rational combination strategies.

On that front, the review surveys a growing arsenal of next-generation designs. Bispecific antibodies (BsAbs) can bind two antigens at once, improving tumor specificity and compensating for heterogeneous expression. Immune-stimulating antibody conjugates (ISACs) replace or augment the cytotoxic payload with immune agonists, converting the delivery platform into a vaccine-like stimulus. Degrader-antibody conjugates (DACs) piggyback on PROTAC technology, protein degradation targeting chimeras, to deliver molecular glues or degraders that eliminate intracellular oncoproteins previously considered undruggable. Dual-payload ADCs carry two mechanistically distinct toxins in one molecule, attacking multiple vulnerabilities simultaneously and complicating the tumor’s escape routes. Each of these platforms addresses a specific failure mode identified in the resistance analysis, reflecting a maturing, mechanism-driven design philosophy.

Combination therapy emerges as another major theme. Because ADC resistance often converges on pathways that other drug classes already target, the review explores rational pairings with tyrosine kinase inhibitors (TKIs), DNA damage response modulators, and immune checkpoint inhibitors (ICIs). The immunological logic is particularly attractive: ADC-induced tumor cell death releases antigens that can prime antitumor immune responses, while checkpoint blockade removes the brakes on the T cells that response activates. In hematological malignancies, the review also discusses ADC use in minimal residual disease (MRD) settings and around hematopoietic stem cell transplantation (HSCT), where their selectivity could help eradicate residual clones, though it notes the need to manage risks such as cytokine release syndrome (CRS) when ADCs are combined with other immune-directed agents.

The review closes with a sober but optimistic outlook. ADCs have already demonstrated, in the words of the clinical record, that precision-targeted cytotoxicity can rescue patients who have failed traditional treatment, and the pace of approvals across breast, lung, and urothelial cancers shows no sign of slowing. But the same analysis shows that the field’s future depends on solving the resistance puzzle at every level, from linker chemistry and bystander payload design to microenvironment remodeling and immune synergy. With the authors supported by Guangdong provincial and national Chinese research funding, the work consolidates a decade of clinical learning into a design manual for what may come next. If the next generation of conjugates delivers on the strategies outlined here, the guided missile metaphor may finally describe what these drugs actually do for the majority of patients, not just the fortunate few.

Subject of Research: Antibody-drug conjugate mechanisms, resistance, and next-generation strategies in cancer targeted therapy

Article Title: Antibody-drug conjugates: mechanism, progress and future directions of cancer targeted therapy

Article References: Li, M., Wu, G., Chen, B., Zheng, Z., Ning, X., Li, J., Zeng, D., Li, J., & Song, J. (2026). Antibody-drug conjugates: mechanism, progress and future directions of cancer targeted therapy. Molecular Cancer. https://doi.org/10.1186/s12943-026-02817-0

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02817-0

Keywords: antibody-drug conjugates, targeted cancer therapy, drug resistance, monoclonal antibodies, cancer drug delivery, trastuzumab deruxtecan, tumor microenvironment, bispecific antibodies, immune checkpoint inhibitors, topoisomerase I inhibitors, triple-negative breast cancer, combination therapy

Hairy cell leukemia is a rare hematological malignancy that affects the blood, bone marrow, spleen, and other organs. First described in the late 1950s, the disease is characterized by the overgrowth of abnormal white blood cells, which crowds out the production of normal blood cells and leaves patients vulnerable to infection, anemia, and bleeding complications. The cancer takes its name from a striking microscopic feature: the malignant cells carry short, thin, hair-like projections on their surface, giving them an unmistakable appearance under the microscope. Approximately 1,200 Americans receive a diagnosis each year, and for reasons that remain unknown, men are affected four times more often than women.

One of the most important conceptual advances in recent years has been the recognition that hairy cell leukemia is not a single disease but two distinct entities: classic hairy cell leukemia and hairy cell leukemia variant. Classic disease is by far the more common form, accounting for up to 90 percent of cases. Thanks to current treatments, most patients with classic hairy cell leukemia remain in remission for five to 15 years or more, a remarkable achievement for a blood cancer that once carried a grim prognosis. Variant disease, by contrast, is far more aggressive. Roughly 10 to 15 percent of patients have the variant form, which tends to respond less well to therapy, relapses more quickly, and carries a poor survival rate. Patients with classic disease who relapse also face a much worse outlook. Closing this gap between the success achieved in classic disease and the unmet needs of variant and relapsed patients is the central focus of the latest round of grants.

The six new awards zero in on a range of aspects of the disease, supporting patients from initial diagnosis and throughout their treatment. At The Ohio State University, Christopher Oakes, Ph.D., is working to advance understanding and classification of hairy cell leukemia in individual patients. Precise classification is the essential first step in ensuring that each patient receives the right treatment, particularly in a rare cancer where expertise is concentrated at a limited number of centers. At Dana-Farber Cancer Institute in Boston, Gregory Abel, M.D., M.P.H., is examining quality of life, decision-making, and outcomes for patients, acknowledging that survival is only one measure of success in a chronic disease that can require repeated courses of therapy.

At Stanford University in California, Gerlinde Wernig, M.D., is focused on finding new methods to improve disease prognosis, including understanding the factors that lead to relapse and to the development of variant disease. Her work addresses one of the deepest questions in the field: why some patients respond beautifully to treatment while others progress to more aggressive forms. At Case Western Reserve University in Cleveland, Reshmi Parameswaran, Ph.D., is examining how hairy cell leukemia becomes resistant to treatment and developing new therapeutic strategies for the variant form. Drug resistance is a central mechanism behind relapse, and unraveling it at the molecular level could open the door to treatments that overcome or prevent it.

Two of the grants support clinical trials testing combination therapies in Europe. Enrico Tiacci, M.D., at the University of Perugia in Italy, will be testing an all-oral combination treatment for patients whose hairy cell leukemia has relapsed. Tiacci’s involvement in this partnership is not new: his groundbreaking earlier work, also supported by research funds from this collaboration, established the drug vemurafenib as an alternative to the chemotherapy-based standard of care. Vemurafenib targets the BRAF mutation that drives the vast majority of classic hairy cell leukemia cases, and its success transformed the treatment landscape for relapsed patients who had exhausted conventional options.

Across the Atlantic, Francesco Forconi, M.D., Ph.D., at the University of Southampton in the United Kingdom, is testing whether a combination of two drugs that inhibit different proteins involved in hairy cell leukemia can produce deep, long-lasting remissions. The ambition behind his trial is a fixed-duration treatment paradigm: patients would stop therapy after a defined period and remain in remission, rather than having to take treatment indefinitely. For a rare cancer where patients may live for decades with their disease, the difference between lifelong therapy and a finite course with durable remission is profound, both medically and in terms of quality of life.

The scale and coordination of the HCL2030 program reflect a deliberate strategy for a rare disease. Because hairy cell leukemia affects relatively few patients, no single institution sees enough cases to drive major advances alone. Lore Gruenbaum, Ph.D., chief scientific officer at Blood Cancer United, emphasized this point, noting that medical research is not a solo sport. Even though researchers are working at different locations across two continents, she said, they are all very much on the same team, and that cooperation is particularly important for rare diseases such as hairy cell leukemia. It takes cooperation, time, and money, she added, to find the advances that will make a real difference for patients.

Anna Lambertson, executive director of the Hairy Cell Leukemia Foundation, framed the grants as the direct result of patient and family commitment to the cause. For patients with classic hairy cell leukemia, she noted, the field has achieved years and often decades of remission. Patients with variant disease, and those who relapse, deserve treatments that work just as well, she said, describing the grants as the way to close that gap. The Hairy Cell Leukemia Foundation, founded in 1984, is the only United States nonprofit solely focused on the disease. Founded and governed by patients, it funds innovative research, advances education, and provides peer support worldwide, and its patient-led mission has helped drive major treatment advances over four decades.

Blood Cancer United, the largest global nonprofit focused on blood cancer patient support, research, and advocacy, has served people affected by more than 100 types of blood cancer since its founding in 1949. The organization funds innovative research, offers free resources and personalized support, and advocates for more accessible and affordable healthcare for all patients. Together, the two organizations have turned the HCL2030 program into a coordinated engine for progress in a cancer that receives little attention relative to its impact on those it affects. With nearly $7 million in new investment now flowing to laboratories and clinics in the United States and Europe, the next five years promise advances in classification, prognosis, drug resistance, and treatment duration that could reshape the outlook for every hairy cell leukemia patient, particularly those with variant disease or relapse who have waited longest for options equal to those enjoyed by the majority.

Subject of Research: New research funding for hairy cell leukemia diagnosis, prognosis, and therapy development

Article Title: Nearly $7 million in new funding accelerates hairy cell leukemia research

Article References: Nearly $7 million in new funding accelerates hairy cell leukemia research. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: hairy cell leukemia, Blood Cancer United, Hairy Cell Leukemia Foundation, HCL2030, blood cancer research grants, variant hairy cell leukemia, vemurafenib, drug resistance, relapse, rare disease funding, combination therapy, all-oral treatment

The drug at the center of the resistance story is ABT-737, a synthetic small molecule that belongs to the BH3-mimetic family. These compounds mimic a short protein segment, the Bcl-2 homology 3 domain, that pro-apoptotic proteins use to latch onto and neutralize their anti-apoptotic relatives. In healthy cells, the Bcl-2 protein family functions as a molecular checkpoint for apoptosis, the programmed self-destruction pathway that eliminates damaged or superfluous cells. The family contains pro-death effectors such as Bak and Bax, which punch holes in the outer mitochondrial membrane to trigger the apoptotic cascade, and anti-apoptotic guardians such as Bcl-2, Bcl-xL, and myeloid cell leukemia-1, or Mcl-1, which sequester those effectors and keep the checkpoint locked. BH3 mimetics pry that lock open. ABT-737 binds Bcl-2, Bcl-w, and Bcl-xL with high affinity, freeing Bak and Bax to initiate mitochondrial outer membrane permeabilization and release cytochrome c.

The fatal flaw of ABT-737, documented repeatedly since its 2005 debut in Nature, is what it cannot bind. Mcl-1 sits outside its reach, and cancer cells respond to Bcl-2 family pressure by leaning harder on Mcl-1 for survival. Prior work has shown that breast cancer cells frequently increase Mcl-1 expression when exposed to ABT-737, and that the drug performs dramatically better in cell lines where Mcl-1 is degraded or genetically silenced. In triple-negative breast cancer specifically, dependence on Mcl-1 has been traced to its canonical anti-apoptotic function, making the protein both a vulnerability and the principal escape route from Bcl-2-targeted therapy. Clinical efforts to develop selective Mcl-1 inhibitors have been beset by cardiac toxicity concerns, which has pushed researchers toward indirect strategies that lower Mcl-1 levels using existing or better-tolerated compounds.

Enter C-phycocyanin, the phycobiliprotein pigment that gives spirulina and other cyanobacteria their distinctive blue-green color. It is not an obscure molecule. Phycocyanin is consumed as a dietary supplement, has been investigated as a natural anti-inflammatory and antioxidant, and has accumulated a growing preclinical dossier of anti-cancer activity across breast, pancreatic, and gastrointestinal tumor models. Earlier studies in triple-negative breast cancer cells, including the aggressive MDA-MB-231 line, showed that the pigment suppresses proliferation and migration through the MAPK signaling pathway. What the new study adds is a precise mechanistic account of how C-phycocyanin interacts with the Bcl-2 family to convert ABT-737 from a partially effective drug into a synergistic killer.

The experimental system was deceptively simple. Shayesteh Khishavand and Hadi Karami cultured MDA-MB-468 cells, a well-characterized triple-negative breast cancer line that carries mutant p53 and an epidermal growth factor receptor amplification, and treated them with C-phycocyanin alone, ABT-737 alone, or the two drugs in combination. They then measured cell viability with MTT assays, proliferation with trypan blue exclusion, migratory capacity with wound healing assays, long-term reproductive survival with clonogenic assays, apoptosis with ELISA-based detection, and caspase-3 enzymatic activity. Expression of the key Bcl-2 family players was quantified at both the messenger RNA level by quantitative reverse transcription PCR and the protein level by Western blot. Drug interactions were formally assessed using the Combination Index method, a widely used framework in which values below one indicate synergy, values near one indicate additivity, and values above one indicate antagonism.

The numbers tell a striking story. On its own, C-phycocyanin inhibited half of the cells at a concentration of 5.62 micromolar, while ABT-737 required 32.47 micromolar to reach the same effect, reflecting the substantial intrinsic resistance of these cells to the BH3 mimetic. When the two agents were combined, the half-maximal inhibitory concentration of the drugs dropped to 3.71 micromolar, and the Combination Index fell below one, formally confirming a synergistic interaction. In practical terms, each drug needed less of itself to do more damage when partnered with the other, exactly the pharmacological profile that combination therapy seeks.

The molecular mechanism underlying that synergy resolved into a familiar pattern of compensatory resistance and its circumvention. When ABT-737 was applied alone, MDA-MB-468 cells raised Mcl-1 expression by roughly 40 percent, a textbook survival response to pressure on the Bcl-2 branch of the family. C-phycocyanin co-treatment effectively counteracted that response, holding Mcl-1 in check. Beyond blunting the adaptive Mcl-1 surge, the pigment also downregulated Bcl-2 itself while simultaneously increasing expression of Bak, the pro-apoptotic effector that ABT-737 liberates, and p53, the tumor suppressor that coordinates apoptotic responses to cellular stress. The net effect was to strip away the anti-apoptotic shielding while boosting the pro-apoptotic force, tilting the Bcl-2 family balance decisively toward mitochondrial breach.

Downstream readouts confirmed that the shift translated into genuine cell death and functional impairment. The combination produced significantly greater caspase-3 activation than either drug alone, indicating that the intrinsic apoptotic cascade had been engaged to completion. Apoptosis measured by ELISA rose in parallel. The partnership also constrained malignant behavior beyond the dish-level kill: cells treated with both drugs migrated far less effectively in wound healing assays and formed markedly fewer colonies, suggesting that the combination impairs both dissemination potential and the self-renewal capacity required for tumor propagation, not merely acute viability.

The authors are appropriately measured about the scope of their findings. The work rests on a single cell line, and MDA-MB-468, with its mutant p53 and EGFR amplification, represents only one molecular identity within the heterogeneous universe of triple-negative breast cancer. The study itself notes that further validation in additional triple-negative cell lines is warranted, and the jump from two-dimensional cultures to animal models and, ultimately, patients remains long and uncertain. C-phycocyanin’s pharmacokinetics, bioavailability, and safety profile at efficacious doses in humans are not established by this work, and ABT-737 itself was succeeded clinically by orally bioavailable derivatives such as navitoclax and venetoclax, which carry their own resistance and toxicity profiles.

Even with those caveats, the study lands at a moment of genuine momentum for apoptosis-targeted cancer therapy. The conceptual advance is that a well-tolerated natural product, rather than a bespoke synthetic Mcl-1 inhibitor, can suppress the compensatory pathway that limits BH3-mimetic efficacy, opening a lower-toxicity route to rational combination design. It also reinforces a principle that has emerged across multiple tumor types: the predictive value of Mcl-1 levels for BH3-mimetic response, and the therapeutic value of manipulating those levels directly. Whether C-phycocyanin can make that leap from pigment to pharmaceutical partner will depend on the validation studies that must now follow, but for a cancer with so few molecular handles, the identification of a new one, plucked from a common blue-green alga, is a result worth watching closely.

Subject of Research: Overcoming ABT-737 resistance in triple-negative breast cancer through C-phycocyanin-mediated Mcl-1 downregulation

Article Title: Overcoming ABT-737 resistance in triple-negative breast cancer: C-phycocyanin-mediated myeloid cell leukemia-1 downregulation enhances apoptotic sensitivity

Article References: Khishavand, S., & Karami, H. (2026). Overcoming ABT-737 resistance in triple-negative breast cancer: C-phycocyanin-mediated myeloid cell leukemia-1 downregulation enhances apoptotic sensitivity. Molecular Biology Reports, 53(1), Article 1614. https://doi.org/10.1007/s11033-026-12824-5

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12824-5

Keywords: triple-negative breast cancer, ABT-737, C-phycocyanin, Mcl-1, BH3 mimetics, apoptosis, drug synergy, Bcl-2 family, combination therapy, MDA-MB-468, caspase-3, natural products

B7-H3, also known by its scientific name CD276, belongs to the B7 family of immune checkpoint proteins, the same extended family that includes the famous PD-L1 target of modern immunotherapy. In many tumors, B7-H3 is displayed at high levels on the cell surface, where it is thought to help the cancer evade immune surveillance. Earlier clinical work had already shown that patients with triple-negative breast cancer whose tumors carry abundant B7-H3 tend to fare worse, but the question of what the molecule actually does inside these cells remained open. The new study set out to answer that question by combining large public datasets, tissue microarrays from patient samples, multiplex immunofluorescence imaging, RNA sequencing, and a battery of genetic perturbation experiments in the laboratory.

The evidence that B7-H3 matters in this disease is striking. Across the datasets and patient tissue analyses, the team found that B7-H3 was consistently elevated in triple-negative tumors compared with normal breast tissue, and that high expression correlated with poorer overall survival and earlier recurrence. When the researchers forced cancer cells to overproduce B7-H3 in culture, the cells became more aggressive on every measure they tested: they migrated farther, invaded through barriers more effectively, formed more colonies in clonogenic growth assays, and resisted apoptosis, the programmed cell death that would normally cull damaged or abnormal cells. Silencing B7-H3 with small interfering RNAs produced the mirror image of these effects, calming the cells down and restoring their vulnerability to death signals.

To find out how B7-H3 exerts these effects, the team turned to RNA sequencing, a technique that reads out the activity of thousands of genes at once. Comparing cells with high and low B7-H3, one gene stood out from the crowd: HSPA8, which encodes a member of the HSP70 family of heat shock proteins. These chaperones are the cell’s folding assistants, stabilizing newly made proteins and protecting clients from stress-induced damage, and cancer cells often lean on them heavily to survive the hostile conditions inside a tumor. When the researchers depleted HSPA8, the malignant phenotypes that B7-H3 overexpression had created largely collapsed, indicating that this chaperone is a critical downstream effector of B7-H3’s tumor-promoting activity.

The next challenge was to trace the path from a cell-surface protein to a chaperone gene inside the nucleus. The team’s experiments pointed to a two-step relay. First, B7-H3 knockdown reduced the phosphorylation of p38 MAPK, a stress-activated kinase that relays signals from the membrane into the cell. Pharmacological inhibition of p38 MAPK reproduced the same molecular changes, lowering both SP1 and HSPA8. Second, the levels of SP1, a well-known transcription factor that binds gene promoters and switches them on, dropped in parallel. Promoter-reporter assays showed that SP1 drives the transcription of the HSPA8 gene, and when the researchers re-introduced SP1 into cells where B7-H3 had been silenced, HSPA8 expression partially recovered, along with the cells’ ability to form colonies and their resistance to apoptosis.

The authors are careful about how far they push this interpretation. Their data, they note, are consistent with p38 MAPK being involved in the pathway, but the phosphorylation and pharmacological experiments do not establish p38 as an obligatory intermediate in a strictly linear signaling cascade from B7-H3 to HSPA8. This kind of caution matters, because signaling networks in cancer cells are notoriously tangled, and a drug that blocks one kinase often triggers compensatory routes. Still, the chain of evidence, from B7-H3 to p38 phosphorylation to SP1 abundance to HSPA8 transcription, offers a coherent mechanistic account of how a surface immune molecule can shape the internal survival machinery of a tumor cell.

Perhaps the most clinically provocative result came from an experiment that stacked the odds against the cancer. When the researchers added HSPA8 knockdown on top of B7-H3 silencing, the malignant phenotypes were suppressed even further than with B7-H3 knockdown alone, suggesting that the two targets act on partially independent vulnerabilities. Translating that idea into a living animal model, the team tested a combination therapy in syngeneic 4T1 tumors, a mouse breast cancer line that recapitulates key features of the human disease. Mice received an antibody against B7-H3, the HSP70-family inhibitor VER155008, both, or neither. Among the four treatment groups, the combination produced the greatest observed reduction in tumor burden, a result that will surely fuel interest in pairing B7-H3-directed immunotherapy with chaperone blockade.

The implications reach beyond triple-negative breast cancer. B7-H3 is overexpressed in a wide range of malignancies, and several B7-H3-targeting agents, including antibodies, antibody-drug conjugates, and CAR-T cell constructs, are already in clinical development for other cancers. If the intracellular program described here, the p38-SP1-HSPA8 axis, operates in other B7-H3-high tumors as well, it could explain why simply blocking the surface molecule has produced mixed results in some trials, and it offers a rationale for rational combinations that attack both the immune-facing and the survival-facing roles of the protein. HSP70 inhibitors, for their part, have struggled to reach the clinic on their own, partly because chaperones are needed by many normal cells; pairing them with a tumor-selective target like B7-H3 could widen the therapeutic window.

There are, of course, substantial gaps between a mouse experiment and an approved regimen. The combination study used a single syngeneic model, and the authors themselves frame combined targeting of B7-H3 and the HSP70 family as a strategy that warrants further investigation rather than a ready-made therapy. Questions remain about toxicity, dosing, biomarkers for selecting patients, and whether the SP1-dependent regulation of HSPA8 holds in human tumors in real time. The study also relied on RNA interference for much of its genetic work, and validation with additional tools such as CRISPR editing or clinical-grade antibodies will be important. Nevertheless, the work exemplifies a growing trend in cancer biology: treating immune checkpoint molecules not merely as shields against T cells but as signaling hubs whose intracellular functions can be drugged.

For patients with triple-negative breast cancer, the study offers something the field badly needs, a new map of dependencies in a disease defined by the absence of targets. By showing that B7-H3 sustains SP1-dependent HSPA8 expression, and that dismantling this axis weakens the cancer’s migratory, invasive, and survival advantages, the researchers have converted a prognostic marker into a mechanistic hypothesis and, potentially, a combination strategy. The next steps, testing chaperone inhibitors alongside B7-H3 antibodies in larger preclinical models and eventually in carefully designed trials, will determine whether this molecular relay can be turned into a clinical weapon. For now, the message is clear: one of immunology’s favorite surface molecules has a secret life inside the tumor cell, and that secret life may be its greatest weakness.

Subject of Research: The role of B7-H3 in sustaining SP1-dependent HSPA8 expression and driving progression in triple-negative breast cancer

Article Title: B7-H3 promotes triple-negative breast cancer progression by sustaining SP1-dependent HSPA8 expression

Article References: Wang, Y., Zhang, F., You, H., Wang, C., Qian, Z., Yang, X., Ning, X., Jiang, Y., Wu, D., Liu, L., Mei, J., Zhao, X., Chen, D., & Zhang, Y. (2026). B7-H3 promotes triple-negative breast cancer progression by sustaining SP1-dependent HSPA8 expression. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04601-x

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04601-x

Keywords: triple-negative breast cancer, B7-H3, CD276, HSPA8, HSP70, SP1, p38 MAPK, VER155008, immunotherapy, chaperone proteins, cancer signaling, combination therapy